signed informed consent

diagnosis of rcc with clear-cell component histology

at least 3 extracranial measurable metastatic lesions per recist

karnofsky performance score >60

patients should have undergone cytoreductive treatment of their rcc at least 6 weeks prior to inclusion

patients should have adequate organ function for tki treatment.

prior systemic treatment for rcc

uncontrolled central nervous metastases

prior radiotherapy interfering with sbrt

any disorder precluding understanding of trial information.